Seco-DUBA manufacturers
- Seco-DUBA
-
- $977.00
-
2026-05-11
- CAS:1227961-59-2
- Purity: 99.81%
- Supply Ability: 10g
|
| | Seco-DUBA Basic information |
| Product Name: | Seco-DUBA | | Synonyms: | Benzamide, N-[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-9-methyl-3H-benz[e]indol-3-yl]carbonyl]imidazo[1,2-a]pyridin-6-yl]-4-hydroxy-;Seco-DUBA;SYD985 | | CAS: | 1227961-59-2 | | MF: | C29H23ClN4O4 | | MW: | 526.97 | | EINECS: | | | Product Categories: | | | Mol File: | 1227961-59-2.mol |  |
| | Seco-DUBA Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | pka | 8.08±0.15(Predicted) | | form | Solid | | color | Light yellow to brown | | InChIKey | VQAFBYLFRCCWNB-GOSISDBHSA-N | | SMILES | C(NC1=CN2C=C(C(N3C4=C(C5=C(C)C=CC=C5C(O)=C4)[C@H](CCl)C3)=O)N=C2C=C1)(=O)C1=CC=C(O)C=C1 |
| | Seco-DUBA Usage And Synthesis |
| Uses | Seco-DUBA is a inactive prodrug form of duocarmycin (DUBA) containing two hydroxyl groups, which can each be used for coupling to an antibody via a linker. Seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs). | | Definition | Duocarmycins (DUMs; A, B1, B2, C1, C2, D1, D2 and SA) are members of an extremely potent group of antitumor antibiotics isolated from Streptomyces sp. The pharmacophore consists of a cyclopropa[c]pyrrolo[3,2-e]indole (CPI) moiety. DUMs B1, B2, C1, C2, D1 and D2 were a seco-type of DUM A and chemically more stable than DUM A[1].
| | in vitro | Seco-DUBA (SK-BR-3 cells; 0.0001 pM~0.01 nM; 144 hours) dose-dependent reduces cell viability and shows equally potent and efficacious as DUBA[1].
Seco-DUBA causes SK-BR-3 (IC50=0.09), SK-OV-3 (IC50=0.43), and SW620 (IC50=0.09) cells to exhibit highly sensitive.
Seco-DUBA (89 μg/kg; i.v.) is likely converted to DUBA almost instantaneously[2]. | | in vivo | Seco-DUBA (89 μg/kg; i.v.) is likely converted to DUBA almost instantaneously[1]. | Animal Model: | Wistar rats[1] | | Dosage: | 89 μg/kg (Pharmacokinetic Analysis) | | Administration: | I.v. | | Result: | Likely converted to DUBA almost instantaneously.
|
| | target | Humanized IgG1, HER-2
Humanized IgG1, 5 T4
Humanized IgG1, CD22
Mouse IgG1; CD56 | | References | [1] Choi T, et al. Structural Influence of Indole C5-N-Substitutents on the Cytotoxicity
of seco-Duocarmycin Analogs. Archives of Pharmacal Research, 2011; 34: 357–367.
[2] Elgersma R, et al. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985. Molecular Pharmaceutics, 2015; 12: 1813–1835. |
| | Seco-DUBA Preparation Products And Raw materials |
|